Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Table 3

From: Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice

Groups Challenge with APP1 Challenge with APP2
  Survival Lung lesion Survival Lung lesion
Control 0/10 Severeb 0/10 Severeb
Group I 9/10 Slighta Severeb 9/10 Slighta Severeb
Group II 5/10 Moderatea Severeb 6/10 Moderatea Severeb
Group III 6/10 Moderatea Severeb 7/10 Moderatea Severeb
  1. a Surviving mice; b Dead mice